Mutations of SF3B1, found in about 10% CLL cases, are predicted to alter the protein’s tertiary structure, hampering the correct high-affinity recognition of the substrates and resulting in the selection of alternative 3′ splice sites. The gene discussed is SF3B1; the disease is B-cell chronic lymphocytic leukemia.